10-Q: Health Catalyst Reports Q3 2024 Results, Revenue Up 3% Year-Over-Year

Health Catalyst's Q3 2024 results show a 3% increase in revenue compared to the same period last year, alongside a reduced net loss.

Summary

• Health Catalyst's total revenue for Q3 2024 reached $76.4 million, a 3% increase from $73.8 million in Q3 2023.
• Technology revenue grew by 6% to $48.7 million, while professional services revenue remained relatively flat at $27.7 million.
• The company's net loss for Q3 2024 was $14.7 million, an improvement from the $22.0 million loss in Q3 2023.
• Adjusted EBITDA for Q3 2024 was $7.3 million, compared to $2.0 million in Q3 2023.
• For the nine months ended September 30, 2024, total revenue was $227.0 million, a 3% increase from $220.9 million in the same period of 2023.
• The net loss for the nine months ended September 30, 2024 was $48.8 million, compared to $87.8 million for the same period in 2023.
• Adjusted EBITDA for the nine months ended September 30, 2024 was $18.2 million, compared to $9.7 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and profitability, with a significant reduction in net losses and improved Adjusted EBITDA. However, there are also some challenges, such as flat professional services revenue and a lower average ARR for new clients, which temper the overall positive sentiment.

Positives

• The company experienced a significant reduction in net losses for both the quarter and the nine-month period.
• Adjusted EBITDA showed substantial improvement year-over-year for both the quarter and the nine-month period.
• Technology revenue continues to grow, indicating strong demand for the company's platform.
• The company's cost reduction initiatives, including the 2023 restructuring plan, are contributing to improved financial performance.
• The company is seeing incremental improvements in the health system end market, with stabilizing operating margins for clients and prospective clients.

Negatives

• Professional services revenue remained flat in Q3 2024 compared to Q3 2023.
• The company continues to operate at a net loss, although the losses are decreasing.
• The average starting annual recurring revenue (ARR) for new DOS Subscription Clients is lower than historical levels.
• The company anticipates a near-term headwind to technology gross margin as clients are migrated to Health Catalyst Ignite.

Risks

• The company faces intense competition in the healthcare solutions market.
• Macroeconomic challenges, including high inflation and interest rates, could negatively impact client spending and demand for the company's solutions.
• The company's ability to manage growth and organizational change is critical to its success.
• The company's reliance on third-party providers for computing infrastructure and data access poses potential risks.
• The company is subject to various healthcare and data privacy regulations, and failure to comply could result in penalties and harm its business.
• The company's debt obligations, including the convertible senior notes and term loan facility, could impact its financial flexibility.
• The company's pricing model may change over time, affecting its ability to attract and retain clients.
• The company's reliance on a limited number of clients for a significant portion of its revenue poses a risk if those clients reduce their spending or terminate their contracts.
• The company's reliance on the internet and telecommunications infrastructure exposes it to potential disruptions and service interruptions.
• The company's use of open-source software could expose it to claims for breach of contract and intellectual property infringement.

Future Outlook

The company anticipates improvement in 2024 bookings metrics relative to 2022 and 2023, with a higher proportion of bookings expected in the fourth quarter of 2024. The company also expects to migrate existing DOS Subscription Clients to the new Health Catalyst Ignite platform over the next two years, which is expected to result in a technology gross margin tailwind over the medium-term, but a near-term headwind.

Management Comments

• The company is proactively responding to the macroeconomic environment with a strategic operating plan that emphasizes offerings and go-to-market approach in areas where it has the most competitive differentiation and where clients are most likely to achieve measurable financial and operational ROI.
• The company believes this focus will enable it to move forward in a position of continued competitive and financial strength.
• The company will continue to refine its strategic operating plan and is continuing to make several investments in research and development, primarily in enhancing the capabilities within Health Catalyst Ignite, in order to maintain its position as a market-leading data platform over the long term.

Industry Context

The healthcare industry is experiencing significant financial strain, with increased labor and supply costs impacting operating margins. Health Catalyst is adapting to these challenges by focusing on solutions that offer near-term financial ROI and by expanding its Tech-enabled Managed Services (TEMS) offering. The company is also migrating clients to its new Health Catalyst Ignite platform, which is expected to improve scalability and modularity.

Comparison to Industry Standards

• While specific industry benchmarks for healthcare data analytics companies are not provided in the document, Health Catalyst's revenue growth of 3% year-over-year is modest compared to some high-growth technology companies, but may be reasonable given the current economic environment and the financial pressures faced by healthcare providers.
• The company's improvement in net loss and Adjusted EBITDA suggests progress in cost management and operational efficiency, which is a positive sign compared to industry trends of increasing costs.
• The company's focus on recurring revenue and long-term contracts aligns with industry best practices for SaaS companies.
• The company's strategic shift towards modular offerings and TEMS reflects an understanding of the evolving needs of healthcare providers, which is a positive sign compared to companies that are not adapting to market changes.
• The company's investment in its next-generation data platform, Health Catalyst Ignite, is consistent with the industry trend of adopting cloud-based solutions and advanced analytics capabilities.

Related Party Transactions

• The company recognized revenue from a related party of $4.2 million and $12.4 million for the three and nine months ended September 30, 2024, respectively. For the three months ended September 30, 2023, the company recognized $4.1 million of revenue from this related party.

Stakeholder Impact

• Shareholders may view the improved financial performance positively, but will be concerned about the ongoing net losses and the potential impact of macroeconomic challenges.
• Employees may be affected by the company's cost reduction initiatives and restructuring plans, but may also benefit from the company's growth and strategic investments.
• Clients may benefit from the company's new Health Catalyst Ignite platform and its focus on solutions that offer near-term financial ROI.
• Suppliers and creditors may be affected by the company's financial performance and its ability to meet its obligations.

Next Steps

• The company will continue to refine its strategic operating plan.
• The company will continue to make investments in research and development, primarily in enhancing the capabilities within Health Catalyst Ignite.
• The company expects to migrate existing DOS Subscription Clients to the new Health Catalyst Ignite platform over the next two years.
• The company will continue to monitor the impact of the macroeconomic environment on its business.

Key Dates

Keywords

healthcare analytics, data platform, technology subscriptions, professional services, adjusted EBITDA, revenue growth, net loss, HIPAA, cybersecurity, cloud computing, Microsoft Azure, Health Catalyst Ignite, data privacy, intellectual property, acquisitions